Vasilios Papademetriou
Georgetown University
356 Papers
2.6K Citations
Vasilios Papademetriou is an academic researcher from Georgetown University. The author has contributed to research in topics: Blood pressure & Medicine. The author has an hindex of 59, co-authored 348 publications. Previous affiliations of Vasilios Papademetriou include University of Washington & Aristotle University of Thessaloniki.
Chat about Author
Papers
Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk A LIFE Substudy
Stanley S. Franklin,Kristian Wachtell,Vasilios Papademetriou,Michael H. Olsen,Richard B. Devereux,F Fyhrquist,Hans Ibsen,Sverre E. Kjeldsen,Björn Dahlöf +8 more
TL;DR: It is hypothesized that losartan was superior to atenolol in reducing cardiovascular events in a lower-risk group (LRG) versus a higher- risk group (HRG) of patients in a Losartan Intervention For Endpoint reduction (LIFE) substudy, independently of blood pressure (BP) reduction.
28
Current Drug Treatment and Treatment Patterns with Antihypertensive Drugs
TL;DR: The 4 major classes of antihypertensive drugs are diuretics, β-blockers, ACE inhibitors and calcium antagonists, and they are the most effective drugs for use in combination therapy.
27
Carotid Baroreceptor Activation for the Treatment of Resistant Hypertension and Heart Failure
TL;DR: This review critically evaluates available data obtained with carotid baroreceptor activation, emphasizing data acquired during the past year, and discusses the advantages and disadvantages as well as the future prospects of this intervention.
27
Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial
Peter E. Linz,Laura C. Lovato,Robert P. Byington,Patrick J. O'Connor,Lawrence A. Leiter,Lawrence A. Leiter,Daniel J. Weiss,Rex W. Force,John R. Crouse,Faramarz Ismail-Beigi,Debra L. Simmons,Vasilios Papademetriou,Henry N. Ginsberg,Marshall B. Elam +13 more
TL;DR: Iiosyncratic and marked reduction in HDL-C can occur in some patients treated with both fenofibrate and TZD, and practitioners should recognize this important potential idiosyncratic reaction and take appropriate corrective action.
27
Acute and Short-Term Effects of a New Calcium Antagonist in Hypertension
James F. Burris,Aldo Notargiacomo,Vasilios Papademetriou,Edward D. Freis +3 more
- 01 May 1982
TL;DR: This preliminary trial indicates that nitrendipine is an effective antihypertensive agent that merits further study.
27